Abstract
Src family tyrosine kinases (SFKs) play key roles in regulating signal transduction in cellular processes. However, hyper-activated SFKs lead to uncontrolled cell proliferation and cancers. For both Src SH2 and SH3 domains involve in the regulation of tumorigenesis signal pathways, the SH2 and SH3 inhibition strategies are expected to block the protein-protein interactions between SFKs and their corporation proteins to abolish the signal transduction. Many inhibitors of SH2 and SH3 domain have been identified. Herein, some predominant examples of these inhibitors are reviewed.
Keywords: Protein tyrosine kinases, Src kinases, SH2, SH3, inhibitor, peptidomimetic, nonpeptide, progress
Current Medicinal Chemistry
Title: Recent Progress of Src SH2 and SH3 Inhibitors as Anticancer Agents
Volume: 17 Issue: 12
Author(s): X.-L. Lu, X. Cao, X.-Y. Liu and B.-H. Jiao
Affiliation:
Keywords: Protein tyrosine kinases, Src kinases, SH2, SH3, inhibitor, peptidomimetic, nonpeptide, progress
Abstract: Src family tyrosine kinases (SFKs) play key roles in regulating signal transduction in cellular processes. However, hyper-activated SFKs lead to uncontrolled cell proliferation and cancers. For both Src SH2 and SH3 domains involve in the regulation of tumorigenesis signal pathways, the SH2 and SH3 inhibition strategies are expected to block the protein-protein interactions between SFKs and their corporation proteins to abolish the signal transduction. Many inhibitors of SH2 and SH3 domain have been identified. Herein, some predominant examples of these inhibitors are reviewed.
Export Options
About this article
Cite this article as:
Lu X.-L., Cao X., Liu X.-Y. and Jiao B.-H., Recent Progress of Src SH2 and SH3 Inhibitors as Anticancer Agents, Current Medicinal Chemistry 2010; 17 (12) . https://dx.doi.org/10.2174/092986710790827861
DOI https://dx.doi.org/10.2174/092986710790827861 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hypoxia Signaling and the Metastatic Phenotype
Current Molecular Medicine Lactoferrin Derived Peptides: Mechanisms of Action and their Perspectives as Antimicrobial and Antitumoral Agents
Mini-Reviews in Medicinal Chemistry MiR-340 Reduces the Accumulation of Amyloid-β Through Targeting BACE1 (β-site Amyloid Precursor Protein Cleaving Enzyme 1) in Alzheimer’s Disease
Current Neurovascular Research Targeting Class IIa HDACs: Insights from Phenotypes and Inhibitors
Current Medicinal Chemistry Enhanced Free Radical Status of Cancer Cells Success and Failure of Prooxidant/Antioxidant Treatment
Current Signal Transduction Therapy Antineoplastic Potential of Medicinal Plants
Recent Patents on Biotechnology Immunotherapies for Parkinson’s Disease: Progression of Clinical Development
CNS & Neurological Disorders - Drug Targets Sphingolipid Metabolism and Drug Resistance in Hematological Malignancies
Anti-Cancer Agents in Medicinal Chemistry The ATP-Binding Cassette Transporter-2 (ABCA2) Increases Endogenous Amyloid Precursor Protein Expression and Abeta Fragment Generation
Current Alzheimer Research Molecular Mechanisms of Thiamine Utilization.
Current Molecular Medicine CD93 and Related Family Members: Their Role in Innate Immunity
Current Drug Targets Recent Trends in Tubulin-Binding Combretastatin A-4 Analogs for Anticancer Drug Development
Current Medicinal Chemistry Natural Product-Derived Small Molecule Activators of Hypoxia-Inducible Factor-1 (HIF-1)
Current Pharmaceutical Design Antidepressants, β-Arrestins and GRKs: From Regulation of Signal Desensitization to Intracellular Multifunctional Adaptor Functions
Current Pharmaceutical Design Oxazolidinones as Chiral Auxiliaries in the Asymmetric 1,4-Conjugate Addition Reaction Applied to the Total Synthesis of Natural Products: A Supplemental Mini-Review
Current Organic Synthesis Inhibitors of Chronically Active Ras: Potential for Treatment of Human Malignancies
Recent Patents on Anti-Cancer Drug Discovery Actions of Melatonin, Its Structural and Functional Analogs in the Central Nervous System and the Significance of Metabolism
Central Nervous System Agents in Medicinal Chemistry Neuroprotective Therapies for Alzheimers Disease
Current Pharmaceutical Design Preclinical Evaluation of no-Carrier-Added [131I]Meta-Iodobenzyl Guanidine, for the Treatment of Tumours Transfected with the Noradrenaline Transporter Gene
Letters in Drug Design & Discovery Interaction Between Estrogen Receptor Alpha and Insulin/IGF Signaling in Breast Cancer
Current Cancer Drug Targets